ANTX - AN2 Therapeutics, Inc.
4.74
-0.060 -1.266%
Share volume: 258,840
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations:
-0.12%
PREVIOUS CLOSE
CHG
CHG%
$4.80
-0.06
-0.01%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-14-2024 | 08-13-2024 | 11-13-2024 | 03-25-2025 | 05-13-2025 | 11-12-2025 | 03-17-2026 | |
| Assets | ||||||||
| Total Assets | 121.260 M | 108.481 M | 97.689 M | 92.087 M | 81.343 M | 67.235 M | 61.950 M | |
| Current Assets | 116.313 M | 107.438 M | 97.689 M | 86.262 M | 69.559 M | 64.016 M | 59.937 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 89.517 M | 77.771 M | 59.922 M | 62.267 M | 47.075 M | 43.918 M | 38.060 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 24.693 M | 26.769 M | 33.504 M | 21.351 M | 19.985 M | 18.003 M | 19.941 M | |
| Total Non-current Assets | 3.904 M | 0.000 | 0.000 | 5.021 M | 11.480 M | 3.219 M | 2.013 M | |
| Property Plant Equipment | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Assets | 4.947 M | 1.043 M | 0.000 | 5.825 M | 11.784 M | 3.219 M | 2.013 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 121.260 M | 108.481 M | 97.689 M | 92.087 M | 81.343 M | 67.235 M | 61.950 M | |
| Total liabilities | 10.663 M | 10.127 M | 10.017 M | 10.238 M | 8.014 M | 6.858 M | 8.890 M | |
| Total current liabilities | 10.663 M | 10.127 M | 10.017 M | 0.000 | 8.014 M | 6.858 M | 8.720 M | |
| Accounts Payable | 2.433 M | 1.885 M | 1.711 M | 3.317 M | 3.073 M | 2.226 M | 3.021 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 170.000 K | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 170.000 K | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 110.597 M | 98.354 M | 87.672 M | 81.849 M | 73.329 M | 60.377 M | 53.060 M | |
| Common stock | 281.616 M | 283.888 M | 285.814 M | 287.594 M | 289.706 M | 292.553 M | 293.953 M | |
| Retained earnings | -171.072 M | -185.507 M | -198.254 M | -205.776 M | -216.425 M | -232.240 M | -240.950 M |